Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

Zhang, Ting; Sun, Jing; Li, Jinying; Zhao, Yunuo; Zhang, Tao; Yang, Ruoning; Ma, Xuelei

doi:10.1186/s12885-021-08363-w

Table 1 Basic characteristics of the included trials

From: Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

First author	Clinical trial registration number	Year	Phase	Sample size	Gender		Age	Treatment	Disease	Assessment (Response)	Assessment (AE)
First author	Clinical trial registration number	Year	Phase	Sample size	Male	Female	Age	Treatment	Disease	Assessment (Response)	Assessment (AE)
Yamamoto, K.	NCT00355472	2010	I	16	8	8	62 (46–69)	mogamulizumab	relapsed CCR4⁺ ATL or PTCL	RECIL	CTCAE
Ishida, T.	NCT00920790	2012	II	27	12	15	64 (49–83)	mogamulizumab	relapsed CCR4⁺ ATL	RECIL	CTCAE
Ogura, M.	NCT01192984	2014	II	37	23	14	64 (33–80)	mogamulizumab	relapsed CCR4⁺ PTCL or CTCL	RECIL	CTCAE
Duvic, M.	NCT00888927	2015	I-II	41	24	17	66 (35–85)	mogamulizumab	CTCL or PTCL	RECIL	CTCAE
Ishida, T.	NCT01173887	2015	II	53	28	25	–	mLSG15 + mogamulizumab or mLSG15	aggressive ATL	RECIL	CTCAE
Kurose, K.	NCT01929486	2015	I	10	–	–	–	mogamulizumab	LC or EC	RECIST	CTCAE
Zinzani, P. L.	NCT01611142	2016	II	38	23	15	58.5 (19–87)	mogamulizumab	PTCL	RECIL	CTCAE
Ishitsuka, K.	UMIN000025368	2017	II	484	258	226	–	mogamulizumab or mogamulizumab with other drugs	ATL and others	RECIL	CTCAE
Kim, Y. H.	NCT01728805	2018	III	372	216	156	64.5 (54–73)	mogamulizumab or vorinostat	CTCL	RECIL	CTCAE
Nakashima, J.	–	2018	–	45	27	18	69 (43–89)	mogamulizumab	relapsed or refractory ATL	RECIL	CTCAE
Phillips, A. A.	NCT01626664	2018	II	34	37	71	53 (22–82)	mogamulizumab, pralatrexate, gemcitabine plus oxaliplatin or DHAP	ATL	RECIL	CTCAE
–	NCT02358473	2018	I	13	5	8	–	mogamulizumab +docetaxel	NSCLC	RECIST	CTCAE
Doi, T.	NCT02476123	2019	I	96	72	24	63 (56–68)	mogamulizumab +nivolumab	NSCLC, SCLC, GC, EC, HCC, PA	RECIST	CTCAE
Cohen, E. E. W.	NCT02444793	2019	I	24	19	5	63.9 (53–75)	mogamulizumab +utomilumab	CRC, NSCLC, OC, SCCHN	RECIST	CTCAE

Abbreviations: ATL adult T-cell leukemia-lymphoma, PTCL peripheral T-cell lymphoma, CTCL cutaneous T-cell lymphoma, LC lung cancer, EC esophageal cancer, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, GC gastric cancer, HCC hepatocellular carcinoma, PA pancreatic adenocarcinoma, CRC colorectal cancer, OC ovarian cancer, SCCHN squamous cell cancer of head and neck, mLSG15 modified LSG15 regimen (VCAP-AMP-VECP: vincristine, cyclophosphamide, doxorubicin and prednisolone; doxorubicin, ranimustine and prednisolone; vindesine, etoposide, carboplatin and prednisolone), AE adverse events, RECIL Response Evaluation Criteria in Lymphoma, RECIST Response Evaluation Criteria in Solid Tumors, CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us